Isomorphic Labs, the AI drug discovery venture spun out of Google’s DeepMind, has successfully raised $600 million in a funding round led by Thrive Capital, with participation from GV and Alphabet. This marks the first external funding for the company since its inception in 2021. The capital will enhance Isomorphic’s AI drug design capabilities and expedite the transition of its drug discoveries into clinical trials. Founded by DeepMind co-founder Demis Hassabis, the company previously partnered with Eli Lilly and Novartis, potentially unlocking $3 billion in milestone payments. Hassabis emphasized that the funding will facilitate the hiring of top-tier research scientists.